Pomide Uses, Dosage, Side Effects and more
Pomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Pomide is more potent than thalidomide (100-times) and lenalidomide (10-times).
| Trade Name | Pomide |
| Availability | Prescription only |
| Generic | Pomalidomide |
| Pomalidomide Other Names | Pomalidomida, Pomalidomide |
| Related Drugs | paclitaxel, Revlimid, Taxol, Velcade, Darzalex, vinblastine, Pomalyst, interferon alfa-2b, Ninlaro, Doxil |
| Weight | 2mg |
| Type | Capsule |
| Formula | C13H11N3O4 |
| Weight | Average: 273.2441 Monoisotopic: 273.074955855 |
| Protein binding | 12-44% protein bound. It is not concentration dependent. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Hetero Healthcare Limited |
| Available Country | India |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Pomide is a thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma.
Pomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Pomide is also used to associated treatment for these conditions: Refractory Multiple Myeloma
How Pomide works
Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.
Toxicity
Most common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia.
Food Interaction
- Take at the same time every day.
- Take with or without food. Administration of pomalidomide with food reduces the AUC and Cmax by 8% and 27%, respectively, and delays Tmax by two and a half hours.
[Moderate] MONITOR: Cigarette smoking may reduce pomalidomide exposure due to induction of CYP450 1A2, the isoenzyme that is responsible for the metabolic clearance of pomalidomide along with CYP450 3A4.
MANAGEMENT: Patients should be advised that smoking may reduce the efficacy of pomalidomide therapy.
Pomide should be taken on an empty stomach, at least 2 hours before or 2 hours after a meal.
Pomide Drug Interaction
Moderate: lactobacillus acidophilus, carfilzomib, bortezomibUnknown: aspirin, charcoal, aspirin, sulfamethoxazole / trimethoprim, daratumumab, dexamethasone, apixaban, furosemide, metoprolol, amlodipine, acetaminophen, clopidogrel, vitamin a topical, lenalidomide, cyanocobalamin, cholecalciferol, ondansetron
Pomide Disease Interaction
Major: thromboembolismModerate: hematologic toxicities, hepatic impairment, neuropathy, renal impairment, smoking, tumor lysis syndrome
Volume of Distribution
Mean apparent volume of distribution (Vd/F), steady-state = 62 - 138 L
Elimination Route
Pomide is generally well absorbed. The major circulating component is the parent compound. Tmax, single oral dose = 2 -3 hours. When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows: AUC(T) = 400 ng.hr/mL; Cmax = 75 ng/mL. Promalidomide accumulates following multiple doses.
Half Life
Healthy subjects = 9.4 hours; Multiple myeloma patients = 7.5 hours.
Clearance
Total body clearance = 7-10 L/hour
Elimination Route
When a single oral dose (2mg) is given to healthy subjects, 73% of the dose was eliminated in urine. 15% of the dose was eliminated in feces. 2% and 8% of the dose eliminated unchanged as pomalidomide in urine and feces, respectively.
